ANI Pharma (ANIP) Tops Q2 EPS by 65c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.28, $0.65 better than the analyst estimate of $0.63. Revenue for the quarter came in at $116.5 million versus the consensus estimate of $97.02 million.

GUIDANCE:

ANI Pharma sees FY2023 EPS of $3.62-$4.11, versus the consensus of $3.32. ANI Pharma sees FY2023 revenue of $425-445 million, versus the consensus of $402.9 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c